Shots:
Neurocrine Biosciences has initiated a P-II study of investigational NBI-1065890 in adults with TD
P-II study of NBI-1065890 will enroll ~100 adults with TD, evaluating efficacy, safety, and tolerability, with the 1EP being change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score at Wk 8
NBI-1065890 is a selective oral VMAT2 inhibitor…
